Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.
about
Loss of PINK1 attenuates HIF-1α induction by preventing 4E-BP1-dependent switch in protein translation under hypoxiaExploring Internal Ribosome Entry Sites as Therapeutic TargetsThe high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's diseaseα-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activityNeuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents.Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein.The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's diseaseExpression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death.Mitochondria: the missing link between preconditioning and neuroprotection.Mitochondrial aconitase knockdown attenuates paraquat-induced dopaminergic cell death via decreased cellular metabolism and release of iron and H₂O₂.Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation.Involvement of inhibitory PAS domain protein in neuronal cell death in Parkinson's disease.Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration.Iron chelation and neuroprotection in neurodegenerative diseases.Hypoxia inducible factor-1 as a target for neurodegenerative diseases.Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke.Prolyl 4-hydroxylases, master regulators of the hypoxia response.Prolyl 4 hydroxylase: a critical target in the pathophysiology of diseases.Hypoxia-inducible factor signalling mechanisms in the central nervous system.Gingerol-induced hypoxia-inducible factor 1 alpha inhibits human prion peptide-mediated neurotoxicity.Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration.Pre- and Perinatal Ischemia-Hypoxia, the Ischemia-Hypoxia Response Pathway, and ADHD Risk.Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease.Regulation of the HIV-1 promoter by HIF-1α and Vpr proteinsA mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration.Competitive HIF Prolyl Hydroxylase Inhibitors Show Protection against Oxidative Stress by a Mechanism Partially Dependent on Glycolysis.Transcriptome profiling of the subventricular zone and dentate gyrus in an animal model of Parkinson's diseaseInhibition of HIF-prolyl-4-hydroxylases prevents mitochondrial impairment and cell death in a model of neuronal oxytosis.Erythropoietin inhibits HIF-1α expression via upregulation of PHD-2 transcription and translation in an in vitro model of hypoxia-ischemia.A possible novel anti-inflammatory mechanism for the pharmacological prolyl hydroxylase inhibitor 3,4-dihydroxybenzoate: implications for use as a therapeutic for Parkinson's disease.The association between chronic obstructive pulmonary disease and Parkinson's disease: a nationwide population-based retrospective cohort study.A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo.Hsp90 Co-chaperone p23 contributes to dopaminergic mitochondrial stress via stabilization of PHD2: Implications for Parkinson's disease.Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson's Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function.Effect of the asthma-chronic obstructive pulmonary disease syndrome on the stroke, Parkinson's disease, and dementia: a national cohort study.Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible FactorsBrain injury induces HIF-1α-dependent transcriptional activation of LRRK2 that exacerbates brain damage
P2860
Q24337840-44099DD8-4B49-45B6-9D94-B89D41641EAEQ26779296-95D85A71-4F26-4956-B9B8-4440402E284CQ28543195-4C3132E2-7F7C-4F1A-AE08-5E802072A6BBQ28572683-4AC570C0-6254-480B-8AAE-CD2062F978CCQ33544048-2334D822-F470-4118-98DF-3B8462E2FD20Q33768106-A06534AE-45BE-4066-B313-E698B48EC79CQ33770294-C7DA8D04-E1A8-4AE1-986B-7C9EAE608149Q33850971-0009D4F4-F8BE-4A97-8368-00BE90D78ECEQ33889585-84280C4A-EAD0-4BB6-AE8F-910CB37991D8Q34073859-3970D327-C8D3-4DC4-A154-0F0FA57C6F4DQ35240549-6B852A8F-A2F4-4F89-A822-B57965D5E90EQ36241237-6368A24E-5996-45D7-AF5B-9D2CBF4AC17CQ37167475-7A12D811-DA35-4E37-861B-1AEBBFB845B8Q37329938-F46C89EE-A6C3-4BA5-8DE6-40172024085BQ37821331-68E0C8B1-5E32-4937-9F40-6B771EC59955Q37921345-EF8B3BD4-E571-4EAF-86E1-1151A5E3F6FFQ37966694-1EB1DA99-9C45-4637-877C-B88AABD03F99Q38074340-1E479F5F-A196-441A-BF76-008243ED2FDAQ38078689-170A5AD0-3AE8-4C10-A909-620F0C7AB7F4Q38089239-C90B8EA5-EBBD-4CC9-9A8B-2770E9E77076Q38102681-DA53E89B-5EB7-4958-94E6-5841962DA5CFQ38108413-9E4C4CD8-2ABF-4437-8B30-1149BAF38171Q38458037-29709696-4DFA-4D06-8BFE-862C8FF5C7EDQ38570991-99832483-A048-4E28-82A5-447F58EA119DQ38751814-AEC7489B-E8AC-4A43-BB73-01DA34ABF1C8Q38779434-7FFACE0F-FF0E-4D63-ABF4-5CC942074703Q38972868-7CAD44F4-83E2-4487-BA66-040D3B49C0DAQ39407652-D625AD1F-82AF-49B4-8F80-3E1659572BD7Q40829609-90D44570-AA62-4261-A6FA-2395694B52E9Q41297120-13FE32E0-2F30-4225-9EEA-920D3CF4E48DQ41923383-899B56C7-F3A1-4988-B6B6-C0F4699F4144Q42008819-3783AA05-5F3D-4AE0-BA14-3A792E079BDEQ42098321-0F59A7E8-7C7E-459B-A3A1-106D7D4C4886Q43693957-EB3C105D-DFA9-4E59-9C6B-952F0536030EQ50987529-54EEA34F-0067-45E0-8823-8859284A4B4DQ51767924-B2A5BC94-15B7-4704-9733-BD0AFFB1E646Q54979172-9EE732D6-0EDF-430A-A8F9-D1CA0F72169FQ55279240-54ED8000-CBC6-4CC9-BDBA-7FD6E6FA7B56Q58575600-35A11E40-7822-4423-83AF-41E7722FD350Q59137953-855E9721-8A10-4A1A-92F9-DE5B1B8F9B14
P2860
Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of prolyl hydroxyla ...... pathway in Parkinson disease.
@en
Inhibition of prolyl hydroxyla ...... pathway in Parkinson disease.
@nl
type
label
Inhibition of prolyl hydroxyla ...... pathway in Parkinson disease.
@en
Inhibition of prolyl hydroxyla ...... pathway in Parkinson disease.
@nl
altLabel
Inhibition of Prolyl Hydroxyla ...... pyridine-induced Neurotoxicity
@en
prefLabel
Inhibition of prolyl hydroxyla ...... pathway in Parkinson disease.
@en
Inhibition of prolyl hydroxyla ...... pathway in Parkinson disease.
@nl
P2093
P2860
P921
P356
P1476
Inhibition of prolyl hydroxyla ...... pathway in Parkinson disease.
@en
P2093
Ambreena Siddiq
Donna W Lee
Julie K Andersen
Lichuan Yang
M Flint Beal
Rajiv R Ratan
Roberto Gwiazda
Subramanian Rajagopalan
P2860
P304
29065-29076
P356
10.1074/JBC.M109.000638
P407
P577
2009-08-13T00:00:00Z